logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Frontline pembrolizumab doubles median survival in advanced lung cancer

KEYNOTE 189 data show benefit across TPS scores at median 18.7-month follow-up.